-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Black Diamond Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2019 to Q3 2024.
- Black Diamond Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $2.57M, a 156% increase year-over-year.
- Black Diamond Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $8.26M, a 47.7% increase year-over-year.
- Black Diamond Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $4.02M, a 2.79% increase from 2022.
- Black Diamond Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $3.91M, a 206% increase from 2021.
- Black Diamond Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $1.28M, a 44.9% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)